Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc (NQ: CNTX )

1.030 +0.050 (+5.10%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,144
Open 1.000
Bid (Size) 0.9500 (4)
Ask (Size) 1.100 (1)
Prev. Close 0.9800
Today's Range 0.9900 - 1.100
52wk Range 0.4703 - 1.690
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 11, 2023
Via Benzinga
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
--News Direct-- 
Via News Direct

Performance

YTD
+52.80%
+52.80%
1 Month
+0.25%
+0.25%
3 Month
-23.13%
-23.13%
6 Month
+66.13%
+66.13%
1 Year
-14.88%
-14.88%

More News

Read More
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
Via TheNewswire.com
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Context Therapeutics to Participate in Two August 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer
Via Benzinga
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
Via AB Newswire
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference
Via ACCESSWIRE
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Difference
Via Benzinga
Context Therapeutics to Participate in Two April 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Context Therapeutics Inc.
Via GlobeNewswire
$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Context Therapeutics And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Insiders Buying AmeriServ Financial And 2 Other Penny Stocks
Via Benzinga
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.